Silo Pharma 8-K: Launches cryptocurrency treasury strategy, appoints advisor

Rhea-AI Filing Summary

Silo Pharma (SILO) filed an 8-K to disclose a strategic shift toward digital assets. On 4 Aug 2025 the Board formed a Cryptocurrency Advisory Board of up to three members to guide a newly adopted cryptocurrency treasury strategy. The Board simultaneously appointed Corwin Yu as the first advisor and executed an agreement granting him 45,000 stock options at an exercise price of $0.7757. The options vest in 12 equal monthly tranches under the Amended & Restated 2020 Omnibus Equity Incentive Plan. A press release announcing the initiative was issued on 5 Aug 2025 and filed as Exhibit 99.1.

No financial results, guidance, or capital-raising transactions were reported. The filing is limited to governance changes and does not alter prior disclosures.

Positive

• Strategic diversification: Establishing a Crypto Advisory Board positions SILO to leverage digital assets for treasury management.
• Aligned incentives: Option grant ties advisor compensation to shareholder value with a staggered 12-month vesting schedule.

Negative

• Increased volatility risk: Cryptocurrency holdings could expose SILO’s balance sheet to price swings and regulatory uncertainty.
• Potential dilution: Issuance of 45,000 options, while small, adds incremental share count.
• Limited disclosure: No information on planned allocation size, custody solutions, or risk controls was provided.

Insights

Financial Analyst

TL;DR: Crypto treasury plan is interesting but immaterial to valuation today.

The creation of a specialized advisory board signals management’s intent to hold or transact in digital assets, potentially altering the company’s liquidity profile and risk exposure. The 45k option award, worth roughly $35k at grant price, is de minimis relative to SILO’s float and market cap, suggesting limited dilution. Absent accompanying details on allocation size, custody, or accounting treatment, investors cannot gauge balance-sheet impact. Overall, news is strategic but not yet financially material.

Corporate Governance Expert

TL;DR: Governance step adds expertise but raises risk-management questions.

Forming a Crypto Advisory Board is a prudent governance measure if the firm plans to hold volatile assets, aligning oversight with specialized knowledge. However, the board currently has only one member, limiting independence and breadth of expertise. Future disclosures should address internal controls, valuation policies, and regulatory compliance to reassure investors. Until those safeguards are detailed, the initiative introduces incremental operational and reputational risk.

false 0001514183 0001514183 2025-08-04 2025-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2025

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41512		27-3046338
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

677 N. Washington Boulevard Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (718) 400-9031

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 4, 2025, the Board of Directors (“Board”) of Silo Pharma, Inc. (the “Company”) approved the establishment of a cryptocurrency advisory board (the “Crypto Advisory Board”) which will initially consists of up to three (3) members in connection with the Company’s cryptocurrency treasury strategy. On August 4, 2025, the Board appointed Corwin Yu as the initial member of the Crypto Advisory Board.

In connection with this initiative, on August 4, 2025, the Company entered into an advisory agreement with Corwin Yu, pursuant to which Mr. Yu will serve on the Crypto Advisory Board. In consideration of Mr. Yu’s services, the Company has agreed to grant him options to purchase 45,000 shares of its common stock at an exercise price of $0.7757 under its Amended and Restated 2020 Omnibus Equity Incentive Plan, which options will vest in 12 equal monthly installments.

On August 5, 2025, the Company issued a press release announcing the launch of a cryptocurrency treasury strategy, the establishment of the Crypto Advisory Board and the appointment of Mr. Yu thereto. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit		Description
99.1		Press Release dated August 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILO PHARMA, INC.
Date: August 5, 2025	By:	/s/ Eric Weisblum
		Eric Weisblum
		Chief Executive Officer

2

FAQ

Why did Silo Pharma (SILO) file an 8-K on August 5, 2025?

To announce the formation of a Cryptocurrency Advisory Board and the appointment of Corwin Yu as its first member.

How many options did Corwin Yu receive from Silo Pharma?

He was granted 45,000 options at an exercise price of $0.7757, vesting monthly over one year.

What is the purpose of Silo Pharma’s new Crypto Advisory Board?

To guide the company’s cryptocurrency treasury strategy as it considers holding or transacting in digital assets.

Does the 8-K include any financial results or earnings guidance?

No. The filing is limited to governance changes and contains no earnings or revenue data.

Will the option grant significantly dilute Silo Pharma shareholders?

The 45,000 options represent a minor percentage of outstanding shares, so immediate dilution is limited.

When was the related press release issued?

Silo Pharma issued the press release on August 5, 2025, filed as Exhibit 99.1.